Hugel, Inc. develops and manufactures biopharmaceuticals in South Korea and internationally. The company offers Botulinum Toxin, a white injectable dry powder in a transparent glass vial for use in the treatment of positive essential eyelid convulsion in adults over 18 years of age; improvement of severe lasso wrinkles associated with corrugator muscles and/or procerus muscle activities in adults aged between 18 and 65; treatment of upper limb stroke; and treatment of dynamic equinus foot deformity in children with cerebral palsy over 2 years of age, as well as improvement of external angles of secondary ideals related to orbicularis oculi muscle activity in adults aged between 19 and 65 under the Botulax, Regenox, Zentox, Reage, Magnion, Hugel Toxin, Juvenlife, Botulim, and Botoshot brands. It also provides hyaluronic acid filler under the Dermalax, and The Chaeum brand names; cosmetics under the Wellage brand; and medical devices under BlueRose brand name. Hugel, Inc. was founded in 2001 and is headquartered in Chuncheon-si, South Korea.
| 265000 | |
| 270000 | |
| - | |
| 270000 | |
| 254500 | |
| 139500-326000 | |
| 2 904 370 M | |
| 11 001 K | |
| 343 494 M | |
| 3570 | |
| 0.575 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Revenue of KRW 84.8bn, operating profit of KRW 34.6bn – 20% and 39.5% YoY growth Solid performance of botulinum toxin in Asia, South America, Australia Booming HA filler sales at home and abroad...R...
Expected to obtain the U.S. FDA's approval in the first quarter of 2024 SEOUL, South Korea, Sept. 1, 2023 /PRNewswire/ -- Hugel, a global total medical aesthetics company, announced that the company ...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
